Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | United States
Approved Indications: None
Known Adverse Events: None
Company: Asociación para Evitar la Ceguera en México
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Retinal Perforations|Epiretinal Membrane
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04490876 |
ILM | N/A |
Completed |
Retinal Detachment|Vitreoretinopathy, Proliferative |
2020-07-25 |
2020-07-31 |
Primary Endpoints|Treatments |
|
NCT01820520 |
RE11-09 | P3 |
Terminated |
Epiretinal Membrane|Retinal Perforations |
2014-02-01 |
2024-05-31 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/01/2022 |
News Article |
Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes |